miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Authors (first, second and last of 20)
Volume 15, issue 1, December 2022
178 articles in this issue
-
-
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
Authors (first, second and last of 33)
-
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer
Authors (first, second and last of 10)
-
Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
Authors (first, second and last of 8)
-
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research
Authors (first, second and last of 9)
-
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Authors (first, second and last of 4)
-
Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Authors (first, second and last of 9)
-
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
Authors (first, second and last of 27)
-
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Authors (first, second and last of 30)
-
Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
Authors (first, second and last of 14)
-
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Authors (first, second and last of 26)
-
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
Authors (first, second and last of 17)
-
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Authors (first, second and last of 11)
-
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
Authors (first, second and last of 21)
-
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
Authors (first, second and last of 9)
-
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
Authors (first, second and last of 23)
-
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study
Authors (first, second and last of 38)
This is part of 2 collections:
-
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis
Authors (first, second and last of 18)
-
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
Authors (first, second and last of 8)
-
-
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor
Authors (first, second and last of 4)
-
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Authors (first, second and last of 13)
-
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation
Authors (first, second and last of 20)
-
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
Authors (first, second and last of 6)
-
Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry
Authors (first, second and last of 9)
-
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Authors (first, second and last of 10)
-
-
-
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Authors (first, second and last of 8)
-
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
Authors (first, second and last of 10)
-
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
Authors (first, second and last of 23)
This is part of 1 collection:
-
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Authors (first, second and last of 6)
-
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
Authors (first, second and last of 10)
-
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Authors (first, second and last of 11)
-
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
Authors (first, second and last of 11)
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Authors (first, second and last of 4)
-
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Authors (first, second and last of 11)
-
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
Authors (first, second and last of 22)
-
The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy
Authors (first, second and last of 8)
-
Gene and cell therapies in China: booming landscape under dual-track regulation
Authors (first, second and last of 7)
-
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Authors (first, second and last of 5)
-
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
Authors (first, second and last of 36)
-
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China
Authors (first, second and last of 25)
-
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Authors (first, second and last of 10)
-
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells
Authors (first, second and last of 4)
-
Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets
Authors (first, second and last of 7)
-
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies
Authors (first, second and last of 10)
-
-
Correction to: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety
Authors (first, second and last of 9)
-
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Authors
